The predictive algorithm correctly classified 83 out of 86 (97%) patients in the WM group and 33 out of 40 (83%) patients in the MZL group based on the selected markers, including percentages of CD43, FMC7, CD38, CD13, and MFI of CD19, FMC7, CD22, CD27 and CD79b. The gene discussed is MS4A1; the disease is marginal zone lymphoma.